

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey IL-17RA/IL-17R protein
Leu33-Trp320, with a C-terminal 6-His tag
Accession # XP_005568119.1

N-terminal Sequence Analysis Leu33

Predicted Molecular Mass 34 kDa

SPECIFICATIONS

SDS-PAGE 59-67 kDa, under reducing conditions.

Activity Measured by its ability to inhibit IL-17-induced IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 0.010-0.100 µg/mL in the presence of 10.0 ng/mL Recombinant Human IL-17 (Catalog # 7955-IL).

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 500 µg/mL in PBS.


Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Bioactivity



Recombinant Cynomolgus Monkey IL-17RA/IL-17R His-tag Protein Bioactivity. Recombinant Cynomolgus Monkey IL-17RA/IL-17R His-tag Protein (Catalog #1 1342-IR) inhibits IL-17-induced IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 0.010-0.100 µg/mL in the presence of 10.0 ng/mL Recombinant Human IL-17 (Catalog # 7955-IL).

SDS-PAGE



Recombinant Cynomolgus Monkey IL-17RA/IL-17R His-tag Protein SDS-PAGE. 2 µg/lane of Recombinant Cynomolgus Monkey IL-17RA/IL-17R His-tag Protein (Catalog # 11342-IR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 59-67 kDa.

BACKGROUND

IL-17 R, also known as IL-17 RA, is a 120 kDa type I transmembrane glycoprotein protein that plays a central role in inflammatory responses (1-3). Mature mouse IL-17 R consists of a 291 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 521 aa cytoplasmic domain (4). The cytoplasmic domain contains a region homologous to the TIR domain of the TLR/IL-1 R family (5). Within the extracellular domain, cynomolgus monkey IL-17RA shares 95% sequence identity with human IL-17RA. While the expression of IL-17 is restricted to activated T cells, IL-17 R exhibits a broad tissue distribution (4). Even in the absence of ligand, IL-17 R exists on the cell surface as a multimer (6). IL-17 R can bind IL-17 but must associate with IL-17 RC to transduce signals (7, 8). Interestingly, human IL-17 R does not appear to form productive complexes with mouse IL-17 RC (8). The IL-17 R can also signal in response to IL-17F (9). IL-17 R ligation promotes T cell activation and the production of IL-6, G-CSF, SCF, and multiple pro-inflammatory chemokines (4, 7, 9, 10). IL-17A and IL-17F synergize with TNF- α in the induction of CXCL1, G-CSF, and IL-6 (9, 11). This effect requires the presence of both TNF RI and TNF RII (9). IL-17 interactions with IL-17 R also inhibit the TNF- α induced up-regulation of fibroblast CCL5 and VCAM-1 (11). CCL5 and VCAM-1 induced effects are differentially sensitive to blockade with IL-17 R specific antibodies, suggesting that IL-17 R triggers divergent intracellular signals (11). *In vivo*, IL-17 R activity is important for increased generation of neutrophils and their recruitment to sites of inflammation (10, 12, 13). IL-17 R is required for host defense against microbial infection and for the progression of arthritis from inflammation to destructive joint erosion (10, 13).

References:

1. Iwakura, Y. and H. Ishigame (2006) *J. Clin. Invest.* **116**:1218.
2. Moseley, T.A. *et al.* (2003) *Cytokine Growth Factor Rev.* **14**:155.
3. Kawaguchi, M. *et al.* (2004) *J. Allergy Clin. Immunol.* **114**:1265.
4. Yao, Z. *et al.* (1995) *Immunity* **3**:811.
5. Novatchkova, M. *et al.* (2003) *Trends Biochem. Sci.* **28**:226.
6. Kramer, J.M. *et al.* (2006) *J. Immunol.* **176**:711.
7. Hymowitz, S.G. *et al.* (2001) *EMBO J.* **20**:5332.
8. Toy, D. *et al.* (2006) *J. Immunol.* **177**:36.
9. McAllister, F. *et al.* (2005) *J. Immunol.* **175**:404.
10. Ye, P. *et al.* (2001) *J. Exp. Med.* **194**:519.
11. Schnyder, B. *et al.* (2005) *Cytokine* **31**:191.
12. Tan, W. *et al.* (2006) *J. Immunol.* **176**:6186.
13. Lubberts, E. *et al.* (2005) *J. Immunol.* **175**:3360.